Amicus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2004
Net Income	-151.58	-236.57	-250.46	-276.85	-356.39	Upgrade
Depreciation & Amortization	7.87	5.34	6.21	8.85	4.78	Upgrade
Share-Based Compensation	86.08	76.51	57.84	49.15	44.43	Upgrade
Other Operating Activities	-11.46	-11.86	-16.08	-14.44	56.77	Upgrade
Operating Cash Flow	-69.09	-166.58	-202.49	-233.29	-250.42	Upgrade
Capital Expenditures	-7.44	-0.36	-3.88	-3.23	-20.01	Upgrade
Change in Investments	105.5	92.67	82.65	-10.35	115.17	Upgrade
Investing Cash Flow	98.06	92.32	78.76	-13.58	95.15	Upgrade
Share Issuance / Repurchase	103.21	4.31	229.21	32.25	201.28	Upgrade
Debt Issued / Paid	-20.96	-0.28	-0.48	230.6	-0.42	Upgrade
Other Financing Activities	-20.57	-11.49	-16.66	-	16.64	Upgrade
Financing Cash Flow	61.68	-7.46	212.07	262.86	217.5	Upgrade
Exchange Rate Effect	6.31	-14.62	-5.05	3.83	1.73	Upgrade
Net Cash Flow	96.96	-96.34	83.29	19.82	63.97	Upgrade
Free Cash Flow	-76.53	-166.93	-206.38	-236.52	-270.43	Upgrade
Free Cash Flow Margin	-19.16%	-50.70%	-67.55%	-90.66%	-148.39%	Upgrade
Free Cash Flow Per Share	-0.26	-0.58	-0.76	-0.91	-1.13	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).